ADCP Bioassay Effector Cell FcγRIIa (H Variant)/ NFAT Luciferase Reporter Jurkat Cell Line

ADCP Bioassay Effector Cell FcγRIIa (H Variant)/NFAT Reporter Jurkat Cells are Jurkat T cells engineered to express firefly luciferase under the control of NFAT response elements, and human FcγRIIa, H variant. This cell line was functionally validated in a ADCP (antibody-dependent cell-mediated phagocytosis) assay.

Figure 1: Illustration of the mechanism of action of ADCP Bioassay Effector Cell FcγRIIa (H Variant)/NFAT Luciferase Reporter Jurkat Cell Line.
ADCP Bioassay Effector Cell FcγRIIa (H Variant)/NFAT Luciferase Reporter Jurkat cells are used as effector cells. The effector cells are co-cultured in the presence of target cells and an antibody of interest. The antibody binds to the target antigen on the target cell whereas its Fc portion binds to FcγRIIa on the cell surface of the effector cell, cross-linking the effector and target cells. Engagement of FcγRIIa leads to the activation of the NFAT pathway in the effector cells. Luciferase activity is proportional to the activation of the ADCP cascade.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.